CR20140545A - Piperazino[1,2-a]indol-1-onas y [1,4]diazepino [1,2-a]indol-1-ona - Google Patents

Piperazino[1,2-a]indol-1-onas y [1,4]diazepino [1,2-a]indol-1-ona

Info

Publication number
CR20140545A
CR20140545A CR20140545A CR20140545A CR20140545A CR 20140545 A CR20140545 A CR 20140545A CR 20140545 A CR20140545 A CR 20140545A CR 20140545 A CR20140545 A CR 20140545A CR 20140545 A CR20140545 A CR 20140545A
Authority
CR
Costa Rica
Prior art keywords
indol
diazepino
onas
piperazino
ona
Prior art date
Application number
CR20140545A
Other languages
English (en)
Spanish (es)
Inventor
Simona M Ceccarelli
Ravi Jagasia
Roland Jakob-Roetne
Juergen Wichmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20140545A publication Critical patent/CR20140545A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
CR20140545A 2012-08-06 2014-11-27 Piperazino[1,2-a]indol-1-onas y [1,4]diazepino [1,2-a]indol-1-ona CR20140545A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12179381 2012-08-06
PCT/EP2013/066344 WO2014023674A1 (en) 2012-08-06 2013-08-05 Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one

Publications (1)

Publication Number Publication Date
CR20140545A true CR20140545A (es) 2015-01-12

Family

ID=48918402

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140545A CR20140545A (es) 2012-08-06 2014-11-27 Piperazino[1,2-a]indol-1-onas y [1,4]diazepino [1,2-a]indol-1-ona

Country Status (24)

Country Link
US (1) US9284321B2 (enExample)
EP (1) EP2880036B1 (enExample)
JP (1) JP5974177B2 (enExample)
KR (1) KR101716062B1 (enExample)
CN (1) CN104540829B (enExample)
AR (1) AR092041A1 (enExample)
AU (1) AU2013301577B2 (enExample)
BR (1) BR112015000313A2 (enExample)
CA (1) CA2880682A1 (enExample)
CL (1) CL2015000143A1 (enExample)
CO (1) CO7141435A2 (enExample)
CR (1) CR20140545A (enExample)
EA (1) EA025884B1 (enExample)
IL (1) IL236808B (enExample)
MA (1) MA37791B1 (enExample)
MX (1) MX362184B (enExample)
MY (1) MY185216A (enExample)
NZ (1) NZ703192A (enExample)
PE (1) PE20150341A1 (enExample)
PH (1) PH12015500059B1 (enExample)
SG (1) SG11201408529VA (enExample)
TW (1) TWI506027B (enExample)
UA (1) UA113013C2 (enExample)
WO (1) WO2014023674A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX362545B (es) * 2013-02-18 2019-01-24 Theranos Ip Co Llc Analisis de imagen y medicion de muestras biologicas.
EP2981538B1 (en) 2013-04-02 2017-08-02 F. Hoffmann-La Roche AG Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one
WO2015036412A1 (en) * 2013-09-12 2015-03-19 F. Hoffmann-La Roche Ag Indol-carboxamide derivatives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1965981C3 (de) * 1968-02-13 1978-08-31 Sumitomo Chemical Co., Ltd., Osaka (Japan) 9-Phenyl-lO-oxopiperazino [l,2-a]-indole und Verfahren zu ihrer Herstellung
GB0106177D0 (en) * 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
GB0202015D0 (en) * 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
ES2333672T3 (es) * 2005-12-09 2010-02-25 F. Hoffmann-La Roche Ag Derivados de amida triciclica para tratamiento de obesidad.
WO2008046072A2 (en) 2006-10-13 2008-04-17 The Board Of Regents Of The University Of Texas System Chemical inducers of neurogenesis
MX2009004898A (es) * 2006-11-09 2009-05-19 Hoffmann La Roche Derivados de indol y de benzofurano-2-carboxamida.
US9095572B2 (en) 2009-01-09 2015-08-04 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
EP2981538B1 (en) * 2013-04-02 2017-08-02 F. Hoffmann-La Roche AG Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one

Also Published As

Publication number Publication date
EA025884B1 (ru) 2017-02-28
WO2014023674A1 (en) 2014-02-13
TW201410679A (zh) 2014-03-16
AR092041A1 (es) 2015-03-18
IL236808B (en) 2018-05-31
AU2013301577B2 (en) 2017-03-30
KR101716062B1 (ko) 2017-03-13
US20150246922A1 (en) 2015-09-03
EP2880036B1 (en) 2017-03-08
MX2015001318A (es) 2015-04-17
MA37791B1 (fr) 2016-12-30
EP2880036A1 (en) 2015-06-10
US9284321B2 (en) 2016-03-15
HK1206355A1 (en) 2016-01-08
BR112015000313A2 (pt) 2017-06-27
CL2015000143A1 (es) 2015-06-19
JP2015524456A (ja) 2015-08-24
CN104540829B (zh) 2017-04-26
MY185216A (en) 2021-04-30
KR20150027832A (ko) 2015-03-12
PH12015500059A1 (en) 2015-03-02
PE20150341A1 (es) 2015-02-28
TWI506027B (zh) 2015-11-01
NZ703192A (en) 2016-04-29
AU2013301577A1 (en) 2014-12-18
CN104540829A (zh) 2015-04-22
MX362184B (es) 2019-01-08
EA201590125A1 (ru) 2015-05-29
UA113013C2 (uk) 2016-11-25
CA2880682A1 (en) 2014-02-13
PH12015500059B1 (en) 2015-03-02
JP5974177B2 (ja) 2016-08-23
MA37791A1 (fr) 2016-05-31
CO7141435A2 (es) 2014-12-12
SG11201408529VA (en) 2015-01-29

Similar Documents

Publication Publication Date Title
CO6831982A2 (es) Pirazolo[4,3-d]pirimidinas útiles como inhibidores de cinasas
CR20140132A (es) Derivados de pirrolopirimidina y purina
CR20140510A (es) Nucleósidos de espirooxetano de uracilo
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
AU2014270524A8 (en) 2-phenylimidazo [1,2-a]pyrimidines as imaging agents
CR20130470A (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO [2,3-d]PIRIMIDINA TROMPOMIOSINA
BR112014029454A2 (pt) síntese de pirrolo [2,3-b] piridinas
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
BR112012019302A2 (pt) imidazo[1,2-b][1,2,4]triazinas como inibidores de c-met
MY191628A (en) Novel triazolo[4,5-d]pyrimidine derivatives
CR20130539A (es) Triazolopiridinas
CU20160004A7 (es) Bencil-1 h-pirazolo[3,4-b]piridinas
UY33888A (es) Derivados de (1,2,4) triazolo [4,3-a) quinoxalina como inhibidores de fosfodiesterasas
CR20130419A (es) Derivados heterocíclicos de amina
CR20140306A (es) Fluormetil -5,6-dihidro-4h-[1,3] oxazinas
CO6852083A2 (es) Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas
CR20150084A (es) 2-oxo-2,3-dihidro-indoles
CR20140435A (es) Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
CR20140094A (es) Derivados de etinilo
UY35218A (es) Compuestos de [1,2,4]triazol e imidazol sustituidos
MY167947A (en) Absorbent article
MX347855B (es) Derivados de anilina, su preparación y su aplicación terapéutica.
CR20140322A (es) Nuevos derivados de bencil sulfonamida útiles como inhibidores de mogat-2
CR20150087A (es) Derivados de pirazol-carboxamida
EP2872143A4 (en) DI AND TRI HETEROARYL DERIVATIVES AS PROTEIN AGGREGATION INHIBITORS